Format

Send to

Choose Destination
Bioorg Med Chem Lett. 2009 Mar 1;19(5):1428-30. doi: 10.1016/j.bmcl.2009.01.032. Epub 2009 Jan 15.

The identification of orally bioavailable thrombopoietin agonists.

Author information

1
Pfizer Global Research and Development, Groton Laboratories, MS8220-2405, Eastern Point Road, Groton, CT 06340, USA.

Abstract

Recently, we disclosed a series of potent pyrimidine benzamide-based thrombopoietin receptor agonists. Unfortunately, the structural features required for the desired activity conferred physicochemical properties that were not favorable for the development of an oral agent. The physical properties of the series were improved by replacing the aminopyrimidinyl group with a piperidine-4-carboxylic acid moiety. The resulting compounds possessed favorable in vivo pharmacokinetic properties, including good bioavailability.

PMID:
19186055
DOI:
10.1016/j.bmcl.2009.01.032
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center